JM
Therapeutic Areas
Aurinia Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| LUPKYNIS (voclosporin) | Lupus Nephritis | Approved/Commercial |
| voclosporin | Focal Segmental Glomerulosclerosis (FSGS) | Phase 2 |
| AUR200 Series | Undisclosed Autoimmune Diseases | Pre-clinical |
Leadership Team at Aurinia Pharmaceuticals
PG
Peter Greenleaf
President and Chief Executive Officer
GM
Gregory M. Keenan, M.D.
Executive Vice President and Chief Medical Officer
MG
Maximilian G. Conway
Executive Vice President and Chief Corporate Officer
MR
Michael R. Martin
Executive Vice President and Chief Operating Officer
SP
Stephen P. Robertson
Executive Vice President, General Counsel, and Corporate Secretary
RT
Robert T. Foster, Pharm.D., Ph.D.
Founder and former CEO (Key Scientific Advisor/Board Member)
GM
George M. Milne, Jr., Ph.D.
Chairman of the Board of Directors
JM
Jill M. Leversage
Member of the Board of Directors
DG
Daniel G. Billen
Member of the Board of Directors
AJ
Andrew J. Sinclair, Ph.D.
Member of the Board of Directors